Key to solving this conundrum will be to stratify poorly differentiated tumours, according to whether they cluster with Lgr5+EPHB2+ ISCs [304] or display methylation of CSC-associated Wnt-target genes [304,341], to identify patients that may benefit from Wnt antagonists or agonists, respectively. This evidence concerns the gene LGR5 and neoplasm.